Onmel generic
Onmel is an antifungal drug owned by Sebela Ireland Ltd. It contains itraconazole as an active ingredient and was first authorized for market use on 29th April, 2010. The company holds a total of 1 patent for Onmel.
When will Onmel generic be available?
The generic version of Onmel could potentially be released after 3rd October, 2028. This is due to the expiry of the patent US8486456 titled 'Itraconazole compositions with improved bioavailability', which is the last patent held by the company for Onmel.
Onmel uses
Onmel is primarily used for the treatment of onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes. itraconazole, the active ingredient in Onmel, helps in combating these fungal infections when used once daily for 12 consecutive weeks.
Onmel patent expiration
Onmel has 1 patent, which is set to expire on 3rd October, 2028. This will allow for the possibility of generic versions of Onmel to be released. The patent held is US8486456 titled 'Itraconazole compositions with improved bioavailability'. Below are the details of the patent: